{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T15:08:16Z","timestamp":1775488096954,"version":"3.50.1"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1097\/iae.0000000000001264","type":"journal-article","created":{"date-parts":[[2016,8,30]],"date-time":"2016-08-30T19:35:30Z","timestamp":1472585730000},"page":"962-970","source":"Crossref","is-referenced-by-count":19,"title":["ROLE OF ADDITIONAL DEXAMETHASONE FOR THE MANAGEMENT OF PERSISTENT OR RECURRENT NEOVASCULAR AGE-RELATED MACULAR DEGENERATION UNDER RANIBIZUMAB TREATMENT"],"prefix":"10.1097","volume":"37","author":[{"given":"Sandra","family":"Rezar-Dreindl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"Eibenberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolf","family":"Buehl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Georgopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guenther","family":"Weigert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Krall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roman","family":"Dunavoelgyi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ursula","family":"Schmidt-Erfurth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Sacu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20-20210130","first-page":"361","article-title":"Ranibizumab: phase III clinical trial results","volume":"19","author":"Rosenfeld","year":"2006","journal-title":"Ophthalmol Clin North Am"},{"key":"R2-20-20210130","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1517\/13543784.15.7.779","article-title":"Promising new treatments for neovascular age-related macular degeneration","volume":"15","author":"Michels","year":"2006","journal-title":"Expert Opin Investig Drugs"},{"key":"R3-20-20210130","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"364","author":"Martin","year":"2011","journal-title":"N Engl J Med"},{"key":"R4-20-20210130","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.ophtha.2009.05.024","article-title":"A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration","volume":"116","author":"Boyer","year":"2009","journal-title":"Ophthalmology"},{"key":"R5-20-20210130","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.ophtha.2011.12.016","article-title":"HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration","volume":"119","author":"Singer","year":"2012","journal-title":"Ophthalmology"},{"key":"R6-20-20210130","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"R7-20-20210130","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1016\/j.ophtha.2013.03.046","article-title":"Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP)","volume":"120","author":"Rofagha","year":"2013","journal-title":"Ophthalmology"},{"key":"R8-20-20210130","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/aos.12463","article-title":"Treating the untreatable patient: current options for the management of treatment-resistant neovascular age-related macular degeneration","volume":"92","author":"Broadhead","year":"2014","journal-title":"Acta Ophthalmol"},{"key":"R9-20-20210130","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1136\/bjophthalmol-2013-303513","article-title":"Non-responders to treatment with antagonists of vascular endothelial growth factor in age-related macular degeneration","volume":"97","author":"Krebs","year":"2013","journal-title":"Br J Ophthalmol"},{"key":"R10-20-20210130","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1016\/j.ophtha.2013.01.073","article-title":"Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials","volume":"120","author":"Jaffe","year":"2013","journal-title":"Ophthalmology"},{"key":"R11-20-20210130","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1001\/jama.293.12.1509","article-title":"Inhibitors of ocular neovascularization: promises and potential problems","volume":"23","author":"Van Wijngaarden","year":"2005","journal-title":"JAMA"},{"key":"R12-20-20210130","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1097\/IAE.0000000000000081","article-title":"Exacerbation of choroidal and retinal pigment epithelial atrophy after anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration","volume":"34","author":"Young","year":"2014","journal-title":"Retina"},{"key":"R13-20-20210130","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.ajo.2007.01.028","article-title":"An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (lucentis) for neovascular age-related macular degeneration","volume":"143","author":"Fung","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"R14-20-20210130","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ajo.2014.09.011","article-title":"Treatment outcomes after 3 years in neovascular age-related macular degeneration using a treat-and-extend regimen","volume":"159","author":"Rayess","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"R15-20-20210130","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/j.1755-3768.2008.01502.x","article-title":"Combined intravitreal bevacizumab and triamcinolone in exudative age-related macular degeneration","volume":"88","author":"Jonas","year":"2010","journal-title":"Acta Ophthalmol"},{"key":"R16-20-20210130","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1016\/j.ophtha.2013.03.016","article-title":"Combination therapy for neovascular age-related macular degeneration refractory to anti-vascular endothelial growth factor agents","volume":"120","author":"Tozer","year":"2013","journal-title":"Ophthalmology"},{"key":"R17-20-20210130","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1089\/jop.2012.0173","article-title":"Bevacizumab and triamcinolone acetonide for choroidal neovascularization due to age-related macular degeneration unresponsive to antivascular endothelial growth factors","volume":"29","author":"Veritti","year":"2013","journal-title":"J Ocul Pharmacol Ther"},{"key":"R18-20-20210130","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1136\/bjophthalmol-2014-306002","article-title":"One year results of a phase 1 study of the safety and tolerability of combination therapy using sustained release intravitreal triamcinolone acetonide andranibizumab for subfoveal neovascular AMD","volume":"99","author":"Lim","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"R19-20-20210130","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1016\/j.ophtha.2008.07.007","article-title":"Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration?","volume":"115","author":"Schaal","year":"2008","journal-title":"Ophthalmology"},{"key":"R20-20-20210130","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1016\/j.ophtha.2011.05.014","article-title":"Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results","volume":"118","author":"Haller","year":"2011","journal-title":"Ophthalmology"},{"key":"R21-20-20210130","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1016\/j.ophtha.2014.04.012","article-title":"Dexamethasone intravitreal implant in the treatment of persistent uveitic macular edema in the absence of active inflammation","volume":"121","author":"Cao","year":"2014","journal-title":"Ophthalmology"},{"key":"R22-20-20210130","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1097\/IAE.0000000000000443","article-title":"Repeated invtravitreal dexamethasone implant (ozurdex) for diabetic macular edema","volume":"35","author":"Scaramuzzi","year":"2015","journal-title":"Retina"},{"key":"R23-20-20210130","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1167\/iovs.10-5285","article-title":"Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant","volume":"52","author":"Chang-Lin","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R24-20-20210130","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ajo.2009.01.024","article-title":"A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study","volume":"148","author":"Lalwani","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"R25-20-20210130","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1001\/archopht.122.2.218","article-title":"Intravitreal reinjection of triamcinolone for exudative age-related macular degeneration","volume":"122","author":"Jonas","year":"2004","journal-title":"Arch Ophthalmol"},{"key":"R26-20-20210130","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000381865","article-title":"Dexamethasone intravitreal implant as adjunctive therapy to ranibizumab in neovascular age-related macular degeneration: a multicenter randomized controlled trial","volume":"234","author":"Kuppermann","year":"2015","journal-title":"Ophthalmologica"},{"key":"R27-20-20210130","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000001264","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T01:17:32Z","timestamp":1620955052000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006982-201705000-00020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000001264","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]}}}